Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ulimorelin
- Development stage
- Phase 3
- Lead developer
- Tranzyme Pharma
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
Ulimorelin is a synthetic, small molecule ghrelin receptor agonist developed as a first-in-class treatment for gastrointestinal motility disorders such as postoperative ileus (POI) and diabetic gastroparesis. It acts by selectively activating the growth hormone secretagogue receptor type 1a (GHSR-1a), stimulating gastric motility and accelerating gastric emptying. Unlike some related agents, ulimorelin has little or no effect on growth hormone release in rats but does stimulate GH and IGF-1 in humans. Ulimorelin demonstrated potent prokinetic effects in animal models and early human studies, but failed to show efficacy in pivotal clinical trials for POI. The drug was primarily developed by Tranzyme Pharma and later Lyric Pharmaceuticals[1][2][3][5][7].
- Other names
- ulimorelinulimorelin hydrochloride
02
Targets
GHSR (Growth hormone secretagogue receptor)
Beyond the preview
Go deeper on ulimorelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ulimorelin.